Role of mitogen-activated protein kinase in Taxol-induced apoptosis in human leukemic U937 cells

Cell Growth and Differentiation

Volumn 9, Issue 9, 1998, Pages 767-776

  Lieu, Chien Hui ^a   Liu, Chang Ching ^a   Yu, Tzu Hsien ^a   Chen, Kuang Den ^a   Chang, Yen Ni ^a   Lai, Yiu Kay ^a  

^a NATIONAL TSING HUA UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; PACLITAXEL;

APOPTOSIS; ARTICLE; CELL CYCLE; DRUG SENSITIVITY; GROWTH INHIBITION; HUMAN; HUMAN CELL; KINETICS; LEUKEMIA CELL; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CA(2+)-CALMODULIN DEPENDENT PROTEIN KINASE; CELL CYCLE; CELL DIVISION; CELL SEPARATION; ENZYME INHIBITORS; EUKARYOTIC CELLS; FLOW CYTOMETRY; G1 PHASE; G2 PHASE; HUMANS; LYMPHOMA, LARGE-CELL, DIFFUSE; MAP KINASE KINASE 1; MAP KINASE KINASE 2; MITOGEN-ACTIVATED PROTEIN KINASE 3; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MITOGEN-ACTIVATED PROTEIN KINASES; MITOSIS; PACLITAXEL; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; PROTEIN-TYROSINE KINASES; S PHASE; TYROSINE; U937 CELLS;

EID: 0031695505     PISSN: 10449523     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Dunton, C. J. New options for the treatment of advanced ovarian cancer. Semin. Oncol., 24: S2-S11, 1997.
2. Seidman, A. D., Hudis, C. A., Raptis, G., Baselga, J., Fennelly, D., and Norton, L. Paclitaxel for breast cancer: the Memorial Sloan-Kettering Cancer Center experience. Oncology (Basel), 11 (Suppl. 2): 20-28, 1997.
3. Rowinsky, E. K., Onetto, N., Canetta, R. M., and Arbuck, S. G. Taxol: the first of the taxanes, an important new class of antitumor agents. Semin. Oncol., 19: 646-662, 1992.
4. Sharma, A., Sharma, U. S., and Straubinger, R. M. Paclitaxelliposomes for intracavitary therapy of intraperitoneal P388 leukemia. Cancer Lett., 107: 265-272, 1996.
5. Seiter, K., Feldman, E. J., Traganos, F., Li, X., Halicka, H. D., Darzynkiewicz, Z., Lederman, C. A., Romero, M. B., and Ahmed, T. Evaluation of in vivo induction of apoptosis in patients with acute leukemia treated on a Phase I study of paclitaxel. Leukemia (Baltimore), 9: 1961-1966, 1995.
6. Horwitz, S. B. Mechanism of action of Taxol. Trends Pharmacol. Sci., 13: 134-136, 1992.
7. Lopes, N. M., Adams, E. G., Pitts, T. W., and Bhuyan, B. K. Cell kill kinetics and cell cycle effects of Taxol on human and hamster ovarian cell lines. Cancer Chemother. Pharmacol., 32: 235-242, 1993.
8. Liebmann, J. E., Cook, J. A., Lipschultz, C., Teaque, D., Fisher, J., and Mitchell, J. B. Influence of cremophor EL on the cell cycle effects of paclitaxel (Taxol) in human tumor cell lines. Cancer Chemother. Pharmacol., 33: 331-339, 1994.
9. Jordan, M. A., Toso, R. J., Thrower, D., and Wilson, L. Mechanism of mitotic block and inhibition of cell proliferation by Taxol at low concentrations. Proc. Natl. Acad. Sci. USA, 90: 9552-9556, 1993.
10. 1 phase by interference with spindle formation without affecting other microtubule functions during anaphase and telophase. Cancer Res., 54: 4355-4361, 1994.
11. Milross, C. G., Mason, K. A., Hunter, N. R., Chung, W. K., Peters, L. J., and Milas, L. Relationship of mitotic arrest and apoptosis to antitumor effect of paclitaxel. J. Natl. Cancer Inst., 88: 1308-1314, 1996.
12. Rowinsky, E. K., Donehower, R. C., Jones, R. J., and Tucker, R. W. Microtubule changes and cytotoxicity in leukemic cell lines treated with Taxol. Cancer Res., 48: 4093-4110, 1988.
13. Bhalla, K., Ibrado, A. M., Tourkina, E., Tang, C., Mahoney, M. E., and Huang, Y. Taxol induces internucleosomal DNA fragmentation associated with programmed cell death in human myeloid leukemia cells. Leukemia (Baltimore), 7: 563-568, 1993.
14. Lieu, C. H., Chang, Y. N., and Lai, Y. K. Dual cytotoxic mechanisms of submicromolar Taxol on human leukemia HL-60 cells. Biochem. Pharmacol., 53: 1583-1596, 1997.
15. Rosaria, M. R., Tiso, G. M., Marchetti, C., Severi, B., and Fabbi, M. Taxol cytotoxicity on human leukemia cell lines is a function of their susceptibility to programmed cell death. Cancer Chemother. Pharmacol., 36: 385-392, 1995.
16. Ding, A., Sanchez, E., and Nathan, C. F. Taxol shares the ability of bacterial lipopolysaccharide to induce tyrosine phosphorylation of microtubule-associated protein kinase. J. Immunol., 151: 5596-5602, 1993.
17. Bogdan, C., and Ding, A. Taxol, a microtubule-stabilizing antineoplastic agent, induces expression of tumor necrosis factor α and interleukin-1 in macrophages. J. Leukoc. Biol., 52: 119-121, 1992.
18. Manthey, C. L., Brandes, M. E., Perera, P. Y., and Vogel, S. N. Taxol increases steady state levels of lipopolysaccharide-inducible genes and protein-tyrosine phosphorylation in murine macrophages. J. Immunol., 149: 2459-2465, 1992.
19. Ding, A., Chen, B., Fuortes, M., and Blum, E. Association of mitogen-activated protein kinases with microtubules in mouse macrophages. J. Exp. Med., 183: 1899-1904, 1996.
20. Wolfson, M., Huang, C. P., and Horwitz, S. B. Taxol induces tyrosine phosphorylation of SHC and its association with GRB2 in murine RAW 264.7 cells. Int. J. Cancer, 70: 248-252, 1997.
21. Das, K. C., and White, C. W. Activation of NF-κ B by antineoplastic agents. Role of protein kinase C. J. Biol. Chem., 272: 14914-14920, 1997.
22. Blagosklonny, M. V., Giannakakou, P., El-Deiry, W. S., Kingston, D. G., Higgs, P. I., Neckers, L., and Fojo, T. Raf-1/bcl-2 phosphorylation: a step from microtubule damage to cell death. Cancer Res., 57: 130-135, 1997.
23. Nishio, K., Arioka, H., Ishida, T., Fukumoto, H., Kurokawa, H., Sata, M., Ohata, M., and Saijo, N. Enhanced interaction between tubulin and microtubule-associated protein 2 via inhibition of MAP kinase and CDC2 kinase by paclitaxel. Int. J. Cancer, 63: 688-693, 1995.
24. Levitzki, A., and Gazit, A. Tyrosine kinase inhibition: an approach to drug development. Science (Washington DC), 267: 1782-1788, 1995.
25. Liu, Y., Bhalla, K., Hill, C., and Priest, D. G. Evidence for involvement of tyrosine phosphorylation in Taxol-induced apoptosis in a human ovarian tumor cell line. Biochem. Pharmacol., 48: 1265-1272, 1994.
26. Ponnathpur, V., Ibrado, A. M., Reed, J. C., Ray, S., Huang, Y., Self, S., Bullock, G., Nawabi, A., and Bhalla, K. Effects of modulators of protein kinase on Taxol-induced apoptosis of human leukemic cells possessing disparate levels of p26BCL-2 protein. Clin. Cancer Res., 1: 1399-1406, 1995.
27. Liu, D., and Wang, L. H. Oncogenes, protein tyrosine kinases, and signal transduction. J. Biomed. Sci., 1: 65-82, 1994.
28. Robinson, M. J., and Cobb, M. H. Mitogen-activated protein kinase pathways. Curr. Opin. Cell Biol., 9: 180-186, 1997.
29. Cano, E., and Mahdevan, L. C. Parallel signal processing among mammalian MAPKs. Trends Biochem. Sci., 20: 117-122, 1995.
30. Ras in IL-3-dependent hematopoietic cells. Oncogene, 15: 619-627, 1997.
31. Watabe, M., Kawazoe, N., Masuda, Y., Nakajo, S., and Nakaya, K. Bcl-2 protein inhibits bufalin-induced apoptosis through inhibition of mitogen-activated protein kinase activation in human leukemia U937 cells. Cancer Res., 57: 3097-3100, 1997.
32. Dudley, D. T., Pang, L., Decker, S. J., Bridges, A. J., and Saltiel, A. R. A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc. Natl. Acad. Sci. USA, 92: 7686-7689, 1995.
33. Cuenda, A., Rouse, J., Doza, Y. N., Meier, R., Cohen, P., Gallagher, T. F., Young, P. R., and Lee, J. C. SB20358 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1. FEBS Lett., 364: 229-233, 1995.
34. Sundstrom, C., and Nilsson, K. Establishment and characterization of a human histocytic lymphoma cell line (U-937). Int. J. Cancer, 17: 565-577, 1976.
35. 2+/ calmodulin-dependent protein kinase II. J. Neurochem., 56: 294-298, 1991.
36. Akiyama, T., Ishida, J., Nakagawa, S., Ogawara, H., Watanabe, S. I., Itoh, N., Shibuya, M., and Fukami, Y. Genistein, a specific inhibitor of tyrosine-specific protein kinases. J. Biol. Chem., 262: 5592-5595, 1987.
37. Toullec, D., Pianetti, P., Coste, H., Belleverge, P., Grand-Perret, T., Ajakane, M., Baudet, V., Boissin, P., Boursier, E., Loriolle, F., Duhamel, L., Charon, D., and Kirilovsky, J. The bisindolylmaleimide GF 109203X is a potent and selective inhibitor of protein kinase C. J. Biol. Chem., 266: 15771-15781, 1991.
38. Chijiwa, T., Mishima, A., Hagiwara, M., Sano, M, Hayashi, K., Inoue, T., Naito, K., Toshioka, T., and Hidaka, H. Inhibition of forskolin-induced neurite outgrowth and protein phosphorylation by a newly synthesized selective inhibitor of cyclic AMP-dependent protein kinase, N-[2-(p-bromocinnamyl-amino)ethyl]-5-isoquinoline-sulfonamide (H-89), of PC12D pheochromocytoma cells. J. Biol. Chem., 265: 5267-5272, 1990.
39. 2+-calmodulin-dependent protein kinase II by K252a and its derivative, KT5926. Biochem. Biophys. Res. Commun., 181: 423-429, 1991.
40. Kovalenko, M., Gazit, A., Bohmer, A., Rorsman, L., Ronnstrand, J., Heldin, C. H., Waltenberger, J., Bohmer, F. D., and Levitzki, A. Selective platelet-derived growth factor kinase blockers reverse cis-transformation. Cancer Res., 54: 6106-6114, 1994.
41. Marshall, C. J. Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell, 80: 179-185, 1995.
42. Hennequin, C., Giocanti, N., and Favaudon, V. S-phase specificity of cell killing by docetaxel (Taxotere) in synchronised HeLa cells. Br. J. Cancer, 71: 1194-1198, 1995.
43. Kung, A. L., Zetterberg, A., Sherwood, S. W., and Schimke, R. T. Cytotoxic effects of cell cycle-specific agents: result of cell cycle perturbation. Cancer Res., 50: 7307-7317, 1990.
44. Herrera, R., Hubbell, S., Decker, S., and Petruzzelli, L. A role for the MEK/ MAPK pathway in PMA-induced cell cycle arrest: modulation of megakaryocytic differentiation of K562 cells. Exp. Cell Res., 238: 407-414, 1998.
45. Pumiglia, K. M., and Decker, S. J. Cell cycle arrest mediated by the MEK/mitogen-activated protein kinase pathway. Proc. Natl. Acad. Sci. USA, 94: 448-452, 1997.
46. 1 phase. Biochem. J., 326: 61-68, 1997.
47. Akiyama, T., Ohuchi, T., Sumida, S., Xu, S. Q., and Toyoshima, K. Phosphorylation of the anti-oncogene products and control of the cell cycle. Tohoku J. Exp. Med., 168: 153-157, 1992.
48. Whelchel, A., Evans, J., and Posada, J. Inhibition of ERK activation attenuates endothelin-stimulated airway smooth muscle cell proliferation. Am. J. Respir. Cell Mol. Biol., 16: 589-596, 1997.
49. Karpova, A. Y., Abe, M. K., Li, J., Liu, P. T., Rhee, J. M., Kuo, W. L., and Hershenson, M. B. MEK1 is required for PDGF-induced ERK activation and DNA synthesis in tracheal myocytes. Am. J. Physiol., 272: L558-L565, 1997.
50. 1/S transition. J. Cell. Physiol., 163: 577-588, 1995.
51. Mosman, T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods, 65: 55-63, 1983.
52. Kerr, J. F. R., Winterford, C. M., and Harmon, B. V. Morphological criteria for identifying apoptosis. In: J. E. Cells (ed.), Cell Biology, Vol. 1, pp. 319-329. San Diego, CA: Academic Press, 1994.
53. Gorczyca, W., Gong, J., and Darzynkiewicz, Z. Detection of DNA strand breaks in individual apoptotic cells by the in situ terminal deoxynucleotidyl transferase and nick translation assays. Cancer Res., 53: 1945-1951, 1993.
54. 1 cell cycle arrest. J. Cell. Physiol., 164: 74-84, 1995.
55. Laemmli, U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (Lond.), 227: 680-685, 1970.